智通财经网·2025-11-06 12:55Core Insights - BeiGene reported a strong performance in Q3 2025, with quarterly revenue exceeding 10 billion RMB, reaching 10.077 billion RMB, a year-on-year increase of 41.1% [1] - The company adjusted its full-year revenue guidance for 2025, now expecting revenue between 36.2 billion RMB and 38.1 billion RMB, driven by the strong market position of its product, Brukinsa (Zebutinib) [1] Financial Performance - In Q3 2025, BeiGene's product revenue was 9.954 billion RMB, up 40.6% year-on-year [1] - For the first three quarters of 2025, total revenue reached 27.595 billion RMB, a 44.2% increase compared to the previous year, surpassing the total revenue of 27.21 billion RMB for the entire year of 2024 [1] - The net profit attributable to shareholders for the first three quarters was 1.139 billion RMB, primarily due to significant product revenue growth and improved cost management [1] Product Performance - Zebutinib's global sales in Q3 2025 were 7.423 billion RMB, a 51.0% increase year-on-year, making it the leading revenue generator in the BTK inhibitor market [2] - In the U.S., Zebutinib sales reached 5.266 billion RMB, up 46.9%, driven by strong demand across all indications [2] - In Europe, Zebutinib sales were 1.165 billion RMB, a 68.2% increase, reflecting market share gains in key countries [2] - In China, Zebutinib maintained its leadership with sales of 661 million RMB, a 36.2% increase [2] R&D Milestones - BeiGene is entering a concentrated phase of R&D, with 20 key milestone events expected in the next 18 months [4] - The company is advancing its BCL2 inhibitor, Sotorasib, with global development plans and has completed patient enrollment for a pivotal trial [4] - The company anticipates starting patient enrollment for a trial comparing Sotorasib combined with Zebutinib against another treatment in H1 2026 [4] Additional Developments - BeiGene's other core product, Tislelizumab, achieved sales of 1.363 billion RMB in Q3 2025, a 16.6% increase [3] - The company is making progress in various innovative therapies for solid tumors, with several clinical trials expected to start in 2026 [6]